MAD2L2 antibody (C-Term)
Quick Overview for MAD2L2 antibody (C-Term) (ABIN6243877)
Target
See all MAD2L2 AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- AA 198-231, C-Term
-
Purification
- This antibody is purified through a protein A column, followed by peptide affinity purification.
-
Immunogen
- This MAD2L2 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 198-231 amino acids from the C-terminal region of human MAD2L2.
-
Isotype
- Ig Fraction
-
-
-
-
Application Notes
- IF: 1:25. WB: 1:1000. IHC-P: 1:25
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Expiry Date
- 6 months
-
-
- MAD2L2 (MAD2 Mitotic Arrest Deficient-Like 2 (MAD2L2))
-
Alternative Name
- MAD2L2
-
Background
- Adapter protein able to interact with different proteins and involved in different biological processes. Mediates the interaction between the error-prone DNA polymerase zeta catalytic subunit REV3L and the inserter polymerase REV1, thereby mediating the second polymerase switching in translesion DNA synthesis. Translesion DNA synthesis releases the replication blockade of replicative polymerases, stalled in presence of DNA lesions. May also regulate another aspect of cellular response to DNA damage through regulation of the JNK-mediated phosphorylation and activation of the transcriptional activator ELK1. Inhibits the FZR1- and probably CDC20-mediated activation of the anaphase promoting complex APC thereby regulating progression through the cell cycle. Regulates TCF7L2-mediated gene transcription and may play a role in epithelial-mesenchymal transdifferentiation.
-
Molecular Weight
- 24334
-
UniProt
- Q9UI95
Target
-